Search research articles
Contact Us
Filters
Showing results (11-20 of 39) with videos related to
Page
of 4
Sort By:
Rheumatology and Therapy
|
March 26, 2018
Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial
Gurjit S Kaeley, Daryl K MacCarter, Janak R Goyal, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 24, 2016
Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Gurjit S Kaeley, Midori J Nishio, Janak R Goyal, et al.
Arthritis Care & Research
|
July 31, 2015
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis
Rubén Burgos-Vargas, Shirley M L Tse, Gerd Horneff, et al.
Inflammatory Bowel Diseases
|
February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry
Edward V Loftus, Walter Reinisch, Remo Panaccione, et al.
United European Gastroenterology Journal
|
May 13, 2022
Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
Ailsa Hart, Geert D'Haens, Mareike Bereswill, et al.
The Journal of Pediatrics
|
July 29, 2018
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease
Gerd Horneff, Marieke M B Seyger, Dilek Arikan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 15, 2025
Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment
Remo Panaccione, Gil Y Melmed, David Drobne, et al.
Advances in Therapy
|
March 14, 2023
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease
Edward V Loftus, Jenny Griffith, Ezequiel Neimark, et al.
Journal of Crohn'S & Colitis
|
December 9, 2023
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies
Jean-Frederic Colombel, Stefan Schreiber, Geert D'Haens, et al.
The American Journal of Gastroenterology
|
June 6, 2018
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry
Geert DʼHaens, Walter Reinisch, Remo Panaccione, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 39) with videos related to
Sort By:
Page
of 4
Rheumatology and Therapy
|
March 26, 2018
Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial
Gurjit S Kaeley, Daryl K MacCarter, Janak R Goyal, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 24, 2016
Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Gurjit S Kaeley, Midori J Nishio, Janak R Goyal, et al.
Arthritis Care & Research
|
July 31, 2015
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis
Rubén Burgos-Vargas, Shirley M L Tse, Gerd Horneff, et al.
Inflammatory Bowel Diseases
|
February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry
Edward V Loftus, Walter Reinisch, Remo Panaccione, et al.
United European Gastroenterology Journal
|
May 13, 2022
Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
Ailsa Hart, Geert D'Haens, Mareike Bereswill, et al.
The Journal of Pediatrics
|
July 29, 2018
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease
Gerd Horneff, Marieke M B Seyger, Dilek Arikan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 15, 2025
Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment
Remo Panaccione, Gil Y Melmed, David Drobne, et al.
Advances in Therapy
|
March 14, 2023
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease
Edward V Loftus, Jenny Griffith, Ezequiel Neimark, et al.
Journal of Crohn'S & Colitis
|
December 9, 2023
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies
Jean-Frederic Colombel, Stefan Schreiber, Geert D'Haens, et al.
The American Journal of Gastroenterology
|
June 6, 2018
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry
Geert DʼHaens, Walter Reinisch, Remo Panaccione, et al.
Page
of 4